A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria

Abstract

Background For uncomplicated Plasmodium falciparum malaria, highly efficacious single-dose treatments are expected to increase compliance and improve treatment outcomes, and thereby may slow the development of resistance. The efficacy and safety of a single-dose combination of artefenomel (800 mg) plus ferroquine (400/600/900/1200 mg doses) for the treatment of uncomplicated P. falciparum malaria were evaluated in Africa (focusing on children ≤ 5 years) and Asia. Methods The study was a randomized, double-blind, single-dose, multi-arm clinical trial in patients aged > 6 months to < 70 years, from six African countries and Vietnam. Patients were followed up for 63 days to assess treatment efficacy, safety and pharmacokinetics. The primary efficacy endpoint was the polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28 in the Per-Protocol [PP] Set comprising only African patients ≤ 5 years. The exposure–response relationship for PCR-adjusted ACPR at Day 28 and prevalence of kelch-13 mutations were explored. Results A total of 373 patients were treated: 289 African patients ≤ 5 years (77.5%), 64 African patients > 5 years and 20 Asian patients. None of the treatment arms met the target efficacy criterion for PCR-adjusted ACPR at Day 28 (lower limit of 95% confidence interval [CI] > 90%). PCR-adjusted ACPR at Day 28 [95% CI] in the PP Set ranged from 78.4% [64.7; 88.7%] to 91.7% [81.6; 97.2%] for the 400 mg to 1200 mg ferroquine dose. Efficacy rates were low in Vietnamese patients, ranging from 20 to 40%. A clear relationship was found between drug exposure (artefenomel and ferroquine concentrations at Day 7) and efficacy (primary endpoint), with higher concentrations of both drugs resulting in higher efficacy. Six distinct kelch-13 mutations were detected in parasite isolates from 10/272 African patients (with 2 mutations known to be associated with artemisinin resistance) and 18/20 Asian patients (all C580Y mutation). Vomiting within 6 h of initial artefenomel administration was common (24.6%) and associated with lower drug exposures. Conclusion The efficacy of artefenomel/ferroquine combination was suboptimal in African children aged ≤ 5 years, the population of interest, and vomiting most likely had a negative impact on efficacy. Trial registration ClinicalTrials.gov, NCT02497612. Registered 14 Jul 2015, https://clinicaltrials.gov/ct2/show/NCT02497612?term=NCT02497612&draw=2&rank=1

A new in vitro checkerboard-parasite reduction ratio interaction assay for early de-risk of clinical development of antimalarial combinations

“…The human patient's data used in this study were obtained from randomised, single-dose, Phase 2b clinical trials as previously described (4) (3). Briefly, male and female African or…”

Toward Selective Anticancer Agents: Ferrocene‐Steroid Conjugates

“…[8] Many ferrocene derivatives, some of which reported by us, were found to exhibit antimicrobial, [11][12][13][14][15][16][17][18][19][20]21] antimalarial, [22] anxiolytic, [23] and central nervous system-stimulating activities. [24] Ferrocifens, a group of organometallic analogs of the anticancer drug tamoxifen which are still under formulation studies, [25] and ferroquine, a promising ferrocene-based antimalarial currently in phase II clinical trials, [26,27] represent two major milestones in developing metallocene-containing drugs. Regrettably, not a single compound of ferrocene is currently approved for clinical use, with the possible exception of ferrocerone, which appears to have at one point been used in the former USSR for treating iron deficiency.…”

Metal Complexes as Antifungals? – From a Crowd-Sourced Compound Library to First In Vivo Experiments

“…Unfortunately, the combination of ferroquine with artefenomel, a new trioxolane drug candidate, did not meet the defined efficacy criteria in this trial. 13 Recently, the Thomas group has described a series of dinuclear ruthenium complexes with promising antimicrobial properties that are now being developed for pre-clinical evaluation as part of a spin-off company. [14][15][16][17][18] While metal-based drugs are still a niche field, the recent increase in both in-depth studies as well as preclinical and clinical investigations into this class of compounds highlights a bright future ahead.…”